Company intelligence / Profile preview

NewPace

Ownership: Private
Development stage: Preclinical

Overview

NewPace is developing a unique platform of wearable and subcutaneous implantable cardioverter defibrillator devices designed to monitor, protect, and treat patients at risk of sudden cardiac arrest both inside and outside the hospital. Their solutions aim to provide both short-term (wearable) and long-term (implantable) protection without leads within the heart. As of now, their products are in development with no reported clinical trial results or regulatory approvals.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Drug pipeline

2 assets

DBelt

Pre-clinical

Indications: Sudden cardiac arrest, Ventricular fibrillation

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on NewPace.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NewPace.

Explore the full profile